




Compromise with lifelong anticoagulation?




Weigh the cumulative risks.

Carpentier-Edwards
PERIMOUNT
Pericardial Bioprosthesis



Edwards
LIFESCIENCES

Why compromise with lifelong anticoagulation?



“Arbitrary cutoffs dictating valve choice based predominately on patient age may not give appropriate weight to patient perspectives.”¹

— David S. Bach, MD

From Mechanical to Biomechanical

Mechanical valves have been the **historic** choice for patients up to 70-years old due to the **limited** durability of **porcine** valves.²

Today, cardiac surgeons have **more options**, with the **durable,^{3,4} anticoagulation-free,^{2*}**



biomechanically engineered **Carpentier-Edwards PERIMOUNT Pericardial Bioprosthesis.**

The PERIMOUNT valves offer proven **long-term durability** up to 20 years,^{3,4} that **exceeds** most cardiac patients' **life expectancy^{5,6}** — **without** the drawbacks of lifelong **anticoagulation.^{2*}**

As demographics and etiologies bring older and sicker patients to surgery,^{5,6} there is increasing evidence that **anticoagulation** therapy carries high **cumulative risks⁷⁻⁹** for many valve patients.

At the same time, **reoperation mortality** has dramatically **decreased,¹⁰** and new intraoperative procedures to **treat atrial fibrillation** have demonstrated their efficacy.¹¹

PERIMOUNT valves' durability exceeds most cardiac patients' life expectancy.^{5,6}




Cumulative risks of lifelong anticoagulation **outweigh reoperation risks⁷⁻⁹**

* For patients who do not require warfarin for other risk factors and after the 3-month usual postoperative period.²

A growing number of patients express their preference for a bioprosthetic valve¹²

A majority of surgeons asked about patient preference agree with this statement.



References:

1. Bach DS. Choice of prosthetic heart valves: update for the next generation. J Am Coll Cardiol 2003;42(10):1717-9.
2. Bonow, et al. AHA/ACC Guidelines. J Am Coll Cardiol 1998;32(5):1486-588.
3. Marchand MA, et al. Fifteen-year experience with the mitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. Ann Thorac Surg 2001;71(5 Suppl):S236-9. Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis 16-year Results. Data on file at Edwards Lifesciences, 2003.
4. Frater RW, et al. Long-term durability and patient functional status of the Carpentier-Edwards Perimount pericardial bioprosthesis in the aortic position. J Heart Valve Dis 1998;7(1):48-53. Carpentier-Edwards PERIMOUNT Aortic Pericardial Bioprosthesis 20-year Results. Data on file at Edwards Lifesciences, 2003.
5. Jones EL, et al. Interaction of age and coronary disease after valve replacement: implications for valve selection. Ann Thorac Surg 1994;58(2):378-84; discussion 384-5.
6. Puvimanasinghe JP, et al. Choice of a mechanical valve or a bioprosthesis for AVR: does CABG matter? Eur J Cardiothorac Surg 2003;23(5):688-95; discussion 695.
7. Wittkowsky AK, et al. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. Pharmacotherapy 2004;24(5):600-5.
8. Sjalander A, et al. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med 2003;254(5):434-8.
9. Birkmeyer NJ, et al. Prosthetic valve type for patients undergoing aortic valve replacement: a decision analysis. Ann Thorac Surg 2000;70(6):1946-52.
10. Potter DD, et al. Risk of repeat mitral valve replacement for failed mitral valve prostheses. Ann Thorac Surg 2004;78(1):67-72.
11. Gillinov AM, et al. Curative surgery for atrial fibrillation: current status and minimally invasive approaches. Expert Rev Cardiovasc Ther 2003;1(4):595-603.
12. 83rd Annual meeting of the American Association for Thoracic Surgery. Research conducted with 104 US surgeons. Data on file at Edwards Lifesciences.



Edwards Lifesciences

Give your patients the gift of a quality life.

Any quotes or citations used in this brochure are taken from an independent third-party publication and are not intended to imply that such third party reviewed or endorsed any of the products of Edwards Lifesciences.

RX only. See instructions for use for full prescribing information.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards Lifesciences, Edwards, the stylized E logo, PERIMOUNT Magna and Tricentrix are trademarks of Edwards Lifesciences Corporation. Carpentier-Edwards, PERIMOUNT, PERIMOUNT Plus, and Starr-Edwards are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark office.

©2005 Edwards Lifesciences LLC
All rights reserved. AR00773

Edwards Lifesciences LLC • One Edwards Way • Irvine, CA 92614 USA • 949.250.2500 • 800.424.3278 • www.edwards.com
Edwards Lifesciences (Canada) • 1290 Central Parkway West, Suite 300 • Mississauga, Ontario • Canada L5C 4R3 • 800.268.3993 • 905.566.4220
Edwards Lifesciences S.A. • Ch. du Glapin 6 • 1162 St-Prex • Switzerland • 41.21.823.4300
Edwards Lifesciences Japan • 2-8 Rokubancho • Chiyoda-ku, Tokyo 102-0085 • Japan • 81.3.5213.5700